{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:48:28Z","timestamp":1790221708485,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Infliximab is currently recommended as a third-line treatment for refractory sarcoidosis. Data in function of clinical phenotype are currently lacking. We evaluated patients\u2019 characteristics and responses to infliximab according to their GenPhenReSa cluster.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We evaluated clinical and biological characteristics of patients diagnosed with sarcoidosis who received infliximab between September 2008 and April 2019 at our centre.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fifty-five patients (median disease duration, 87 months) received infliximab: 48 (87%) as a second- or third-line treatment, and 7 (13%) as a first-line treatment. After a median duration of 12 months, 24 (45%) and 14 (25%) patients achieved complete and partial responses, respectively, together with a significant decrease in the number of affected organs and tapering of steroid doses. All patients with neurosarcoidosis (OR 17), 90% in group 2 (ocular-cardiac-cutaneous-CNS, OR 7.4), and approximately two-thirds of those in groups 1 (abdominal organs), 4 (pulmonary-lympho-nodal), and 5 (extrapulmonary), achieved a response, whereas patients in group 3 (musculoskeletal-cutaneous) had a treatment-failure OR of 9. Infliximab could be stopped after complete remission was achieved in 7 patients: 4 relapsed after a median of 6 months. Overall, 36% of patients experienced serious adverse events, mainly infections, which led to treatment cessation in 29% of patients and caused two deaths.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Other than patients with musculoskeletal-cutaneous involvement (group 3), infliximab led to a good response for patients with CNS (group 2) and liver (group 1) organ-predominant sarcoidosis. However, it led to serious infections and merely suspended sarcoidosis, so further research on factors predictive of relapse is needed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-024-02758-6","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T18:03:27Z","timestamp":1710439407000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and safety of Infliximab in systemic sarcoidosis according to GenPhenReSa organ-involvement phenotype: a retrospective study of 55 patients"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0254-3394","authenticated-orcid":false,"given":"Etienne","family":"Rivi\u00e8re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Jourde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Gensous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Demant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Duffau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Merci\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Viallard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estibaliz","family":"Lazaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"key":"2758_CR1","doi-asserted-by":"crossref","unstructured":"Narula N, Iannuzzi M, Sarcoidosis. Pitfalls and challenging mimickers. Front Med. 2021;7:594275.","DOI":"10.3389\/fmed.2020.594275"},{"issue":"23","key":"2758_CR2","first-page":"00156","volume":"S0002\u20139343","author":"MA Judson","year":"2023","unstructured":"Judson MA. The management of sarcoidosis in the 2020s by the primary care physician. Am J Med. 2023;S0002\u20139343(23):00156\u20130.","journal-title":"Am J Med"},{"key":"2758_CR3","unstructured":"Schupp JC, Freitag-Wolf S, Bargagli E et al. Phenotypes of organ involvement in sarcoidosis. Eur Respir J 2018;51(1)."},{"issue":"10","key":"2758_CR4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/17476348.2019.1655401","volume":"13","author":"D Bennett","year":"2019","unstructured":"Bennett D, Bargagli E, Refini RM, Rottoli P. New concepts in the pathogenesis of sarcoidosis. Expert Rev Respir Med. 2019;13(10):981\u201391.","journal-title":"Expert Rev Respir Med"},{"issue":"1","key":"2758_CR5","first-page":"36","volume":"115","author":"RP Baughman","year":"1990","unstructured":"Baughman RP, Strohofer SA, Buchsbaum J, Lower EE. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med. 1990;115(1):36\u201342.","journal-title":"J Lab Clin Med"},{"issue":"4","key":"2758_CR6","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/0091-6749(93)90352-G","volume":"91","author":"M Steffen","year":"1993","unstructured":"Steffen M, Petersen J, Oldigs M, et al. Increased secretion of tumor necrosis factor-alpha, interleukin-1-beta, and interleukin-6 by alveolar macrophages from patients with sarcoidosis. J Allergy Clin Immunol. 1993;91(4):939\u201349.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2758_CR7","first-page":"185","volume":"19","author":"MW Ziegenhagen","year":"2002","unstructured":"Ziegenhagen MW, Rothe ME, Zissel G, M\u00fcller-Quernheim J. Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19(3):185\u201390.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"9","key":"2758_CR8","first-page":"4620","volume":"168","author":"DR Roach","year":"2002","unstructured":"Roach DR, Bean AGD, Demangel C, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol Baltim Md 1950. 2002;168(9):4620\u20137.","journal-title":"J Immunol Baltim Md 1950"},{"issue":"2","key":"2758_CR9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.semarthrit.2017.03.005","volume":"47","author":"Y Jamilloux","year":"2017","unstructured":"Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C, et al. Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients. Semin Arthritis Rheum. 2017;47(2):288\u201394.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"2758_CR10","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.semarthrit.2018.10.005","volume":"48","author":"BL Adler","year":"2019","unstructured":"Adler BL, Wang CJ, Bui T-L, Schilperoort HM, Armstrong AW. Anti-tumor necrosis factor agents in sarcoidosis: a systematic review of efficacy and safety. Semin Arthritis Rheum. 2019;48(6):1093\u2013104.","journal-title":"Semin Arthritis Rheum"},{"key":"2758_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejim.2022.12.003","volume":"109","author":"M Rezaee","year":"2023","unstructured":"Rezaee M, Zangiabadian M, Soheili A, et al. Role of anti-tumor necrosis factor-alpha agents in treatment of sarcoidosis: a meta-analysis. Eur J Intern Med. 2023;109:42\u20139.","journal-title":"Eur J Intern Med"},{"issue":"155","key":"2758_CR12","doi-asserted-by":"publisher","first-page":"190146","DOI":"10.1183\/16000617.0146-2019","volume":"29","author":"FF Rahaghi","year":"2020","unstructured":"Rahaghi FF, Baughman RP, Saketkoo LA, et al. Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. Eur Respir Rev. 2020;29(155):190146.","journal-title":"Eur Respir Rev"},{"issue":"6","key":"2758_CR13","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1183\/09031936.00051907","volume":"31","author":"MA Judson","year":"2008","unstructured":"Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J. 2008;31(6):1189\u201396.","journal-title":"Eur Respir J"},{"issue":"1","key":"2758_CR14","first-page":"19","volume":"31","author":"MA Judson","year":"2014","unstructured":"Judson MA, Costabel U, Drent M, et al. The WASOG sarcoidosis Organ Assessment Instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):19\u201327.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"7","key":"2758_CR15","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.rmr.2010.06.011","volume":"27","author":"F Jounieaux","year":"2010","unstructured":"Jounieaux F, Chapelon C, Valeyre D, et al. Infliximab et sarco\u00efdose chronique. L\u2019exp\u00e9rience fran\u00e7aise \u00e0 propos de 31 cas. Rev Mal Respir. 2010;27(7):685\u201392.","journal-title":"Rev Mal Respir"},{"issue":"1","key":"2758_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.semarthrit.2012.10.008","volume":"43","author":"E Russell","year":"2013","unstructured":"Russell E, Luk F, Manocha S, et al. Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy. Semin Arthritis Rheum. 2013;43(1):119\u201324.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"2758_CR17","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1183\/09031936.00055213","volume":"43","author":"ADM Vorselaars","year":"2014","unstructured":"Vorselaars ADM, Verwoerd A, van Moorsel CHM, et al. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur Respir J. 2014;43(2):602\u20139.","journal-title":"Eur Respir J"},{"issue":"4","key":"2758_CR18","first-page":"509","volume":"33","author":"C Chapelon-Abric","year":"2015","unstructured":"Chapelon-Abric C, Saadoun D, Biard L, et al. Long-term outcome of infliximab in severe chronic and refractory systemic sarcoidosis: a report of 16 cases. Clin Exp Rheumatol. 2015;33(4):509\u201315.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"2758_CR19","first-page":"201","volume":"23","author":"MD Rossman","year":"2006","unstructured":"Rossman MD, Newman LS, Baughman RP, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23(3):201\u20138.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"7","key":"2758_CR20","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","volume":"174","author":"RP Baughman","year":"2006","unstructured":"Baughman RP, Drent M, Kavuru M, et al. Infliximab Therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795\u2013802.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"2758_CR21","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamadermatol.2017.1162","volume":"153","author":"V Heidelberger","year":"2017","unstructured":"Heidelberger V, Ingen-Housz-Oro S, Marquet A, et al. Efficacy and tolerance of Anti-tumor Necrosis factor \u03b1 agents in cutaneous sarcoidosis: a French study of 46 cases. JAMA Dermatol. 2017;153(7):681\u20135.","journal-title":"JAMA Dermatol"},{"issue":"20","key":"2758_CR22","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1212\/WNL.0000000000004644","volume":"89","author":"JM Gelfand","year":"2017","unstructured":"Gelfand JM, Bradshaw MJ, Stern BJ, et al. Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series. Neurology. 2017;89(20):2092\u2013100.","journal-title":"Neurology"},{"issue":"5","key":"2758_CR23","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00415-017-8444-9","volume":"264","author":"F Cohen Aubart","year":"2017","unstructured":"Cohen Aubart F, Bouvry D, Galanaud D, et al. Long-term outcomes of refractory neurosarcoidosis treated with infliximab. J Neurol. 2017;264(5):891\u20137.","journal-title":"J Neurol"},{"issue":"1","key":"2758_CR24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cardfail.2020.08.013","volume":"27","author":"NA Gilotra","year":"2021","unstructured":"Gilotra NA, Wand AL, Pillarisetty A, et al. Clinical and imaging response to tumor necrosis factor alpha inhibitors in treatment of Cardiac Sarcoidosis: a Multicenter experience. J Card Fail. 2021;27(1):83\u201391.","journal-title":"J Card Fail"},{"key":"2758_CR25","doi-asserted-by":"crossref","unstructured":"Bakker ALM, Mathijssen H, Azzahhafi J et al. Effectiveness and safety of infliximab in cardiac Sarcoidosis. Int J Cardiol 2021;S0167527321002758.","DOI":"10.1016\/j.ijcard.2021.02.022"},{"issue":"3","key":"2758_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.semarthrit.2015.05.010","volume":"45","author":"L Riancho-Zarrabeitia","year":"2015","unstructured":"Riancho-Zarrabeitia L, Calvo-R\u00edo V, Blanco R, et al. Anti-TNF-\u03b1 therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients. Semin Arthritis Rheum. 2015;45(3):361\u20138.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"2758_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1183\/09031936.00227014","volume":"46","author":"ADM Vorselaars","year":"2015","unstructured":"Vorselaars ADM, Crommelin HA, Deneer VHM, et al. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. Eur Respir J. 2015;46(1):175\u201385.","journal-title":"Eur Respir J"},{"issue":"1","key":"2758_CR28","first-page":"49","volume":"27","author":"NJ Sweiss","year":"2010","unstructured":"Sweiss NJ, Barnathan ES, Lo K, et al. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27(1):49\u201356.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"6","key":"2758_CR29","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2217\/imt.15.25","volume":"7","author":"HA Crommelin","year":"2015","unstructured":"Crommelin HA, Vorselaars AD, van Moorsel CH, et al. Is there evidence for anti-TNF drugs in joint involvement in sarcoidosis? Immunotherapy. 2015;7(6):601\u2013601.","journal-title":"Immunotherapy"},{"issue":"6","key":"2758_CR30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1055\/s-2002-36520","volume":"23","author":"DA Zisman","year":"2002","unstructured":"Zisman DA, Shorr AF, Lynch JP. Sarcoidosis involving the musculoskeletal system. Semin Respir Crit Care Med. 2002;23(6):555\u201370.","journal-title":"Semin Respir Crit Care Med"},{"key":"2758_CR31","doi-asserted-by":"crossref","unstructured":"H\u00e9mar V, Lazaro E, Viallard J-F et al. Clinical images: sarcoid dactylitis. Arthritis Rheumatol Hoboken NJ. 2020.","DOI":"10.1002\/art.41212"},{"issue":"2","key":"2758_CR32","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1378\/chest.08-1347","volume":"135","author":"E Stagaki","year":"2009","unstructured":"Stagaki E, Mountford WK, Lackland DT, Judson MA. The treatment of Lupus Pernio. Chest. 2009;135(2):468\u201376.","journal-title":"Chest"},{"issue":"6","key":"2758_CR33","first-page":"447","volume":"3","author":"HS Te","year":"2007","unstructured":"Te HS, Campbell L, Chohan S. Infliximab therapy for hepatic and intestinal sarcoidosis. Gastroenterol Hepatol. 2007;3(6):447\u201352.","journal-title":"Gastroenterol Hepatol"},{"issue":"4","key":"2758_CR34","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1002\/hep.28966","volume":"65","author":"M Sebode","year":"2017","unstructured":"Sebode M, Weidemann S, Wehmeyer M, Lohse AW, Schramm C. Anti-TNF-\u03b1 for necrotizing sarcoid granulomatosis of the liver: Sebode et al. Hepatology. 2017;65(4):1410\u20132.","journal-title":"Hepatology"},{"issue":"1","key":"2758_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.rmed.2013.11.019","volume":"108","author":"MA Judson","year":"2014","unstructured":"Judson MA, Baughman RP, Costabel U, Mack M, Barnathan ES. The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial. Respir Med. 2014;108(1):189\u201394.","journal-title":"Respir Med"},{"key":"2758_CR36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.rmed.2016.04.011","volume":"115","author":"HA Crommelin","year":"2016","unstructured":"Crommelin HA, van der Burg LM, Vorselaars ADM, et al. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab. Respir Med. 2016;115:72\u20137.","journal-title":"Respir Med"},{"issue":"s4","key":"2758_CR37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1046\/j.1365-2036.1999.00027.x","volume":"13","author":"Sb Hanauer","year":"1999","unstructured":"Hanauer Sb. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999;13(s4):16\u201322.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2758_CR38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12931-022-01971-5","volume":"23","author":"A Sakkat","year":"2022","unstructured":"Sakkat A, Cox G, Khalidi N, et al. Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis. Respir Res. 2022;23(1):54.","journal-title":"Respir Res"},{"key":"2758_CR39","doi-asserted-by":"crossref","unstructured":"Lhote R, Annesi-Maesano I, Nunes H et al. Clinical phenotypes of extrapulmonary sarcoidosis: an analysis of a French, multiethnic, multicenter cohort. Eur Respir J 2020.","DOI":"10.1183\/13993003.01160-2020"},{"issue":"2","key":"2758_CR40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jbspin.2019.10.001","volume":"87","author":"M Rubio-Rivas","year":"2020","unstructured":"Rubio-Rivas M, Franco J, Corbella X. Sarcoidosis presenting with and without L\u00f6fgren\u2019s syndrome: clinical, radiological and behavioral differences observed in a group of 691 patients. Joint Bone Spine. 2020;87(2):141\u20137.","journal-title":"Joint Bone Spine"},{"issue":"4","key":"2758_CR41","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/JLB.5A0321-162R","volume":"111","author":"R Lepzien","year":"2022","unstructured":"Lepzien R, Nie M, Czarnewski P, et al. Pulmonary and blood dendritic cells from sarcoidosis patients more potently induce IFN\u03b3-producing Th1 cells compared with monocytes. J Leukoc Biol. 2022;111(4):857\u201366.","journal-title":"J Leukoc Biol"},{"key":"2758_CR42","doi-asserted-by":"crossref","unstructured":"Lepzien R, Liu S, Czarnewski P et al. Monocytes in sarcoidosis are potent tumour necrosis factor producers and predict disease outcome. Eur Respir J 2021;58(1).","DOI":"10.1183\/13993003.03468-2020"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-02758-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-024-02758-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-02758-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T18:04:23Z","timestamp":1710439463000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-024-02758-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2758"],"URL":"https:\/\/doi.org\/10.1186\/s12931-024-02758-6","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,14]]},"assertion":[{"value":"20 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our institutional review board (CHU de Bordeaux &amp;amp; Universit\u00e9 de Bordeaux) approved our research (MR-004, French Government).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors gave consent to publish the present work. There is no identifying images or other personal or clinical details of participants presented that compromise anonymity.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None declared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}